Multivariate analysis of infections according to prednisone-equivalent dose of glucocorticoids for initial treatment of acute GVHD
| Type of infection . | 1 mg/kg per day versus 2 mg/kg per day . | |
|---|---|---|
| HR (95% CI) . | P . | |
| Invasive fungal (n = 82) | 0.59 (0.3-1.0) | .06 |
| Gram-positive (n = 291) | 0.71 (0.5-1.0) | .07 |
| Gram-negative (n = 61) | 1.55 (0.8-2.9) | .15 |
| CMV reactivation (n = 288) | 1.06 (0.8-1.4) | .69 |
| CMV disease (n = 38) | 0.68 (0.3-1.5) | .35 |
| Respiratory viruses (n = 66) | 1.21 (0.7-2.1) | .52 |
| EBV (n = 31) | 0.55 (0.2-1.4) | .21 |
| Type of infection . | 1 mg/kg per day versus 2 mg/kg per day . | |
|---|---|---|
| HR (95% CI) . | P . | |
| Invasive fungal (n = 82) | 0.59 (0.3-1.0) | .06 |
| Gram-positive (n = 291) | 0.71 (0.5-1.0) | .07 |
| Gram-negative (n = 61) | 1.55 (0.8-2.9) | .15 |
| CMV reactivation (n = 288) | 1.06 (0.8-1.4) | .69 |
| CMV disease (n = 38) | 0.68 (0.3-1.5) | .35 |
| Respiratory viruses (n = 66) | 1.21 (0.7-2.1) | .52 |
| EBV (n = 31) | 0.55 (0.2-1.4) | .21 |
Adjusted for GVHD grade at onset of treatment (I vs IIa vs IIb vs ≥ III), gut GVHD at onset (any vs none), patient age (continuous variable), donor type (unrelated versus other), donor/recipient HLA mismatch (any vs other) and sex mismatch (female donor with male recipient vs other), conditioning intensity (myeloablative vs nonmyeloablative), use of tacrolimus as part of the GVHD prophylaxis, year of transplantation (continuous variable), concurrent use of BDP and systemic glucocorticoids, and transplantation-to-treatment interval (continuous variable).
CMV indicates cytomegalovirus; and EBV, Epstein-Barr virus.